MyHealthChecked PLC Additional Boots agreement for D2/D8 testing (7525Y)
May 17 2021 - 1:00AM
UK Regulatory
TIDMMHC
RNS Number : 7525Y
MyHealthChecked PLC
17 May 2021
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
MyHealthChecked Plc
("MyHealthChecked" or the "Company")
Additional Boots agreement for Day 2 & Day 8 testing
Extends supply of COVID-19 testing services for international
arrivals to the UK
MyHealthChecked Plc (AIM: MHC), the consumer home-testing
healthcare company, announces it has on 16 May signed a second
contract with Boots UK Limited ("Boots"), the health and beauty
retailer and pharmacy group, to supply the MyHealthChecked(TM)
COVID-19 at-home nasal swab kit, laboratory testing service and
logistics for day two and day eight ("D2/D8") coronavirus testing
for international arrivals.
The contract with Boots for the D2/D8 testing service will run
parallel, and be complementary, to the Company's pre-existing
agreement, announced on 6 April 2021 . MyHealthChecked is currently
the only at-home PCR testing kit provider within Boots for General
Testing and Fit-to-Fly services, launched on 7 April, and now
expands the offering within Boots to include D2/D8 tests that will
be available to purchase online, via www.boots.com across the UK,
from May 17.
The MyHealthChecked(TM) COVID-19 testing kit allows customers to
take a nasal swab themselves at home and send samples safely and
securely via the Royal Mail Tracked 24 service to be tested using
established laboratory-based PCR detection methods. D2/D8 testing
is undertaken at the Manchester-based laboratories of
MyHealthChecked and Yourgene Health plc (AIM: YGEN), with any
sequencing required for positive day 2 samples that meet the DHSC
sequencing criteria, undertaken at Yourgene Health plc. PCR results
are provided to customers within 24-48 hours, via a secure online
portal.
The Agreement is on a non-exclusive basis and has an initial
term of 12 months from 17 May 2021, with a one-month notice period
for termination thereafter.
The contract is expected to have a significant impact on the
future performance of the MHC business and whilst volumes are
unquantified at this stage, the Board believes it is likely to
result in substantial revenue growth in the current financial year
ending 31 December 2021.
MyHealthChecked(TM) also offers the testing kits online via
www.myhealthchecked.com .
Penny McCormick, Chief Executive Officer of MyHealthChecked Plc,
said: "This is another milestone for MyHealthChecked as currently
Boots' only at-home testing kit provider for COVID-19, and we are
delighted to build on our pre-existing agreement as the nation
begins to open up and we anticipate the possibility of travel with
the introduction of the traffic light system. The D2/D8 contract is
a testament to the service that MyHealthChecked provides as we
pride ourselves on the quality and accuracy of our tests, as well
as our operations and customer service.
"We look forward to continuing our partnership with Boots and
while it is still in its infancy, we hope to update the market
imminently as we deliver on this contract."
MyHealthChecked plc www.myhealthchecked.com
P enny McCormick , Chief Executive via Walbrook PR
Officer
Maddy Kennedy, Chief Financial
Officer
SPARK Advisory Partners Limited Tel: +44 (0)20 3368 3550
(NOMAD)
Neil Baldwin
Oberon Capital Ltd (Broker) Tel: +44 (0)203 179 5344
Mike Seabrook mikeseabrook@oberoninvestments.com
Walbrook PR Ltd (Media & Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com
IR)
Paul McManus Mob: +44(0)7980 541 893
About MyHealthChecked PLC ( www.myhealthcheckedplc.com )
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted
pioneering UK healthcare company focused on a range of at-home
healthcare and wellness tests.
MyHealthChecked is the umbrella brand of a range of at-home DNA
and RNA tests, now in development following the acquisition of The
Genome Store in November 2020. The tests will be made available
online, and would be viable for over the counter purchase.
The MyHealthChecked portfolio has been identified as part of a
change in mindset as customers become more familiar with the
concept of accessible healthcare in the growing at home testing kit
market with a focus on accessibility at the right price, led by
UK-based experts.
Glossary:
PCR: polymerase chain reaction
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRSFLFEMEFSEFI
(END) Dow Jones Newswires
May 17, 2021 02:00 ET (06:00 GMT)
Concepta (LSE:CPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Concepta (LSE:CPT)
Historical Stock Chart
From Apr 2023 to Apr 2024